Share |
News

Verisante Technology, Inc. to Present at 2nd Global Life Sciences Conference in Warsaw and Announces change in Board


September 25, 2014 at 3:00 pm

VANCOUVER, BRITISH COLUMBIA - Verisante Technology, Inc. (TSX-V: VRS, OTCQX: VRSEF) (the “Company” or “Verisante”), a leader in cancer detection technology, today announced that Thomas Braun, President & CEO will present at the upcoming 2nd Global Life Sciences Conference in Warsaw on October 2, 2014 at the trading floor of the Warsaw Stock Exchange, Warsaw, Poland.  

Warsaw, the financial capital of Central and Eastern Europe, is a major center of life science investment. On October 2nd, at the Global Life Sciences Conference, over 100 leading life science institutional investors, fund managers and analysts from Central and Eastern Europe will gather in Warsaw to discuss and assess new investment opportunities. They will have access there to Verisante’s management through a corporate presentation and small group meetings.

The organizers of this event are: WDM Capital, Wedbush Europe and the Filipex Enterprises. The partners of this event are: Warsaw Stock Exchange, Wedbush, Wierzbowski Eversheds and Crescendo Communications. For more information please visit: http://lscwarsaw.com

The Company also announced that effective immediately, Joe Biegel has resigned from the Board of Directors and Dr. Branko Palcic has been appointed to the Board.  

“I wish to thank Joe for his invaluable contribution to Verisante over the years.  The Company has immensely benefited from his insights and experience and I wish him all success in his future endeavours”, said Thomas Braun.  “I’d also like to thank Dr. Branko Palcic for accepting a Board appointment.  Verisante will benefit from Dr. Palcic’s experience in clinical affairs as we move forward with regulatory filings in different territories”.

The Company also issued 250,000 stock options to Dr. Palcic and 250,000 stock options each to the remaining three members of the Board of Directors to replace Stock Options held by the directors that expired.  The options shall have an exercise price of $0.14 per share and a term of five years.

About Dr. Branko Palcic, Ph.D.

Dr. Branko Palcic holds a Ph.D. in Biophysics from McMaster University.  He is currently a Professor Emeritus, Department of Integrative Oncology, BC Cancer Agency and was an Honorary Professor at the Department of Pathology and Laboratory Medicine as well as Adjunct Professor at the Department of Physics of the University of British Columbia.  He was the founder and Senior Scientist of the Cancer Imaging Department, as well as the Director of Technology Development with the BC Cancer Agency.  Dr. Palcic’s research interests include the development of methods for detection, diagnosis, and prognosis of early cancer and precancerous lesions of different tissue sites. 

About Verisante Technology, Inc.

Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform, while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. Aura™ has been approved for sale in Canada, Europe and Australia. Core™ has not yet been approved for sale.

Verisante Aura™ was awarded the 2014 North American Technology Innovation of the Year Award for In Vivo Cancer Detection by Frost & Sullivan,  Popular Science Magazine’s “Best of What’s New Award” for 2011, awarded a2013 Prism Award for Innovation in Photonics and an Edison Award for Excellence in Innovation in 2013. Verisante Core™ was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society.

The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Company Contact:                                                                                          

Thomas Braun, President & CEO                                                                              
Verisante Technology, Inc.                                                                         
Telephone: (604) 605-0507                                                                       
Email: info@verisante.com                                                                         
Website:  www.verisante.com                                                                 
YouTube:  www.youtube.com/verisante                                                             
Twitter: www.twitter.com/verisante
Facebook: www.facebook.com/verisante 

Forward Looking Statements

This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

  Back to top